JUPITER, Fla. - Dyadic International , Inc. (NASDAQ:DYAI), a biotechnology company, announced today an agreement with a leading global biopharmaceutical company to use Dyadic's C1 microbial protein production platform for the design and production of recombinant proteins. The agreement is fully funded by the undisclosed partner, which also holds a commercial option.
Dyadic's C1 technology leverages a filamentous fungal system, particularly Thermothelomyces heterothallica, to produce biopharmaceuticals. This platform is recognized for its potential to hasten development, reduce manufacturing costs, and enhance the scalability of biologic vaccines and drugs for human and animal health.
The company's CEO, Mark Emalfarb, expressed optimism about the platform's increasing acceptance, especially following promising Phase I human trial data for a recombinant vaccine developed using the C1 technology. Emalfarb anticipates that this advancement will drive further interest and adoption of the C1 platform.
Dyadic is focused on expanding its global outreach, aiming to address unmet clinical needs by advancing its proprietary microbial platform technologies. The company is actively building a pipeline of products including recombinant human and bovine albumin, biologic vaccines, and antibodies.
This collaboration is part of Dyadic's strategy to meet the increasing demand for protein bioproduction and to offer cost-effective and accessible solutions for both developed and emerging markets. The company also developed the Dapibus™ platform for non-pharmaceutical applications, such as food and nutrition.
The information provided in this article is based on a press release statement from Dyadic International, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.